articleAnnals of OncologyMay 19, 2023HYBRID OA

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

IRI. Ray-CoquardALAlexandra LéarySPSandro PignataCCClaire CropetAGAntonio González-Martı́n

Centre Léon Bérard · Arcagy Gineco · +49 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

•First PARPi trial to show clinically meaningful OS benefit in HRD+ (BRCA/non-BRCA) newly diagnosed advanced ovarian cancer.•5-Year OS rate in HRD+ disease was 66% with olaparib + bevacizumab versus 48% with placebo + bevacizumab.•Forty-six percent of HRD+ patients receiving olaparib + bevacizumab were progression free at 5 years, versus 19% on bevacizumab alone.•No new safety signals were observed, and the incidence of myelodysplastic syndrome/acute myeloid leukemia remained low.•Maintenance olaparib + bevacizumab as a standard of care may enhance potential for cure for HRD+ disease in this setting. BackgroundIn the PAOLA-1/ENGOT-ov25 primary analysis, maintenance olaparib plus bevacizumab demonstrated a…

Citation impact

331
total citations
FWCI
71.73
Percentile
100%
References
30
Citations per year

Authors

30

Topics & keywords

Topics
Keywords
  • Medicine
  • Olaparib
  • Bevacizumab
  • Ovarian cancer
  • Oncology
  • Internal medicine
  • First line
  • Overall survival
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding